MDXH vs. PSNL, SERA, BDSX, XGN, OPGN, BNR, ENZ, ACON, BGLC, and NTRA
Should you be buying MDxHealth stock or one of its competitors? The main competitors of MDxHealth include Personalis (PSNL), Sera Prognostics (SERA), Biodesix (BDSX), Exagen (XGN), OpGen (OPGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), Aclarion (ACON), BioNexus Gene Lab (BGLC), and Natera (NTRA). These companies are all part of the "medical laboratories" industry.
MDxHealth vs.
MDxHealth (NASDAQ:MDXH) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
In the previous week, MDxHealth and MDxHealth both had 1 articles in the media. MDxHealth's average media sentiment score of 1.00 beat Personalis' score of 0.79 indicating that MDxHealth is being referred to more favorably in the media.
MDxHealth has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
MDxHealth presently has a consensus target price of $6.50, indicating a potential upside of 306.25%. Personalis has a consensus target price of $7.80, indicating a potential upside of 144.51%. Given MDxHealth's higher possible upside, research analysts clearly believe MDxHealth is more favorable than Personalis.
Personalis received 110 more outperform votes than MDxHealth when rated by MarketBeat users. Likewise, 68.31% of users gave Personalis an outperform vote while only 55.56% of users gave MDxHealth an outperform vote.
61.9% of Personalis shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 3.8% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MDxHealth has a net margin of -49.52% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat MDxHealth's return on equity.
MDxHealth has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.
Summary
MDxHealth and Personalis tied by winning 8 of the 16 factors compared between the two stocks.
Get MDxHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MDxHealth Competitors List
Related Companies and Tools
This page (NASDAQ:MDXH) was last updated on 4/20/2025 by MarketBeat.com Staff
Buy MDXH Stock Free MDXH Stock Alerts